C4 Therapeutics, Inc. (NASDAQ:CCCC – Get Free Report) CFO Kendra Adams sold 45,173 shares of the company’s stock in a transaction on Thursday, November 12th. The shares were sold at an average price of $2.71, for a total value of $122,418.83. Following the completion of the sale, the chief financial officer owned 337,150 shares of the company’s stock, valued at approximately $913,676.50. The trade was a 11.82% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
C4 Therapeutics Price Performance
Shares of C4 Therapeutics stock opened at $2.76 on Monday. The business’s fifty day simple moving average is $3.13 and its 200-day simple moving average is $3.24. C4 Therapeutics, Inc. has a 52 week low of $1.69 and a 52 week high of $5.17. The firm has a market cap of $362.43 million, a PE ratio of -3.83 and a beta of 3.16.
C4 Therapeutics (NASDAQ:CCCC – Get Free Report) last released its earnings results on Thursday, November 5th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.03. The company had revenue of $8.47 million during the quarter, compared to the consensus estimate of $8.52 million. C4 Therapeutics had a negative return on equity of 37.71% and a negative net margin of 282.22%. As a group, equities analysts expect that C4 Therapeutics, Inc. will post -0.73 earnings per share for the current year.
Institutional Trading of C4 Therapeutics
Institutional investors and hedge funds have recently modified their holdings of the business. SummitTX Capital L.P. purchased a new position in shares of C4 Therapeutics during the 1st quarter worth approximately $28,000. CTC Alternative Strategies Ltd. purchased a new position in C4 Therapeutics during the first quarter worth $28,000. Jefferies Financial Group Inc. acquired a new stake in shares of C4 Therapeutics during the third quarter valued at $34,000. Sei Investments Co. acquired a new stake in shares of C4 Therapeutics during the first quarter valued at $66,000. Finally, China Universal Asset Management Co. Ltd. increased its position in C4 Therapeutics by 27.6% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 22,447 shares of the company’s stock worth $70,000 after purchasing an additional 4,850 shares in the last quarter. Hedge funds and other institutional investors own 78.81% of the company’s stock.
Analysts Set New Price Targets
CCCC has been the subject of several research reports. Guggenheim initiated coverage on C4 Therapeutics in a report on Friday, November 6th. They issued a “buy” rating and a $6.00 target price for the company. Lake Street Capital began coverage on shares of C4 Therapeutics in a report on Wednesday, October 28th. They set a “buy” rating and a $11.00 price target for the company. JPMorgan Chase & Co. assumed coverage on shares of C4 Therapeutics in a research report on Friday, October 9th. They set an “overweight” rating and a $10.00 target price on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of C4 Therapeutics in a research note on Thursday, October 15th. Finally, Evercore cut shares of C4 Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, November 2nd. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, C4 Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $8.50.
Check Out Our Latest Research Report on C4 Therapeutics
About C4 Therapeutics
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts. Founded in 2015, it develops medicines designed to selectively remove disease-causing proteins, with a focus on cancer. The company uses its TORPEDO platform to design targeted protein degraders. These molecules are intended to bind a target protein and recruit the cell’s natural protein-disposal machinery, leading to the protein’s breakdown. C4 Therapeutics’ research and development programs include oral small-molecule candidates for oncology.
Featured Articles
- Five stocks we like better than C4 Therapeutics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for C4 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C4 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
